// Workers AI · dad joke modeWhat did Camicinal say? It's a chemical reaction.

Camicinal
Clinical data
Other names	GSK962040
Identifiers
	IUPAC name 1-{4-[(3-Fluorophenyl)amino]-1-piperidinyl}-2-(4-{[(3S)-3-methyl-1-piperazinyl]methyl}phenyl)ethanone;
CAS Number	923565-21-3;
PubChem CID	15984937;
ChemSpider	13116304;
UNII	3C8348951H;
KEGG	D10330;
CompTox Dashboard (EPA)	DTXSID901025606 ;
ECHA InfoCard	100.158.139
Chemical and physical data
Formula	C25H33FN4O
Molar mass	424.564 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@H]1CN(CCN1)CC2=CC=C(C=C2)CC(=O)N3CCC(CC3)NC4=CC(=CC=C4)F;
	InChI InChI=1S/C25H33FN4O/c1-19-17-29(14-11-27-19)18-21-7-5-20(6-8-21)15-25(31)30-12-9-23(10-13-30)28-24-4-2-3-22(26)16-24/h2-8,16,19,23,27-28H,9-15,17-18H2,1H3/t19-/m0/s1; Key:RZKDEGZIFSJVNA-IBGZPJMESA-N;

Camicinal was a motilin agonist investigated for the treatment of gastroparesis.^[1]^[2]^[3] It did not improve enteral feeding intolerance.^[4]

References

↑ Barshop K, Kuo B (January 2015). "The investigational drug camicinal for the treatment of gastroparesis". Expert Opinion on Investigational Drugs. 24 (1): 133–140. doi:10.1517/13543784.2015.975792. PMID 25341626. S2CID 25896703.
↑ Hobson R, Farmer AD, Dewit OE, O'Donnell M, Hacquoil K, Robertson D, et al. (November 2015). "The effects of camicinal, a novel motilin agonist, on gastro-esophageal function in healthy humans-a randomized placebo controlled trial". Neurogastroenterology and Motility. 27 (11): 1629–37. doi:10.1111/nmo.12663. PMID 26348542.
↑ Chapman MJ, Deane AM, O'Connor SL, Nguyen NQ, Fraser RJ, Richards DB, et al. (August 2016). "The effect of camicinal (GSK962040), a motilin agonist, on gastric emptying and glucose absorption in feed-intolerant critically ill patients: a randomized, blinded, placebo-controlled, clinical trial". Critical Care. 20 (1): 232. doi:10.1186/s13054-016-1420-4. PMC 4967996. PMID 27476581.
↑ Deane AM, Lamontagne F, Dukes GE, Neil D, Vasist L, Barton ME, Hacquoil K, Ou X, Richards D, Stelfox HT, Mehta S, Day AG, Chapman MJ, Heyland DK (2018). "Nutrition Adequacy Therapeutic Enhancement in the Critically Ill: A Randomized Double-Blind, Placebo-Controlled Trial of the Motilin Receptor Agonist Camicinal (GSK962040): The NUTRIATE Study". Journal of Parenteral and Enteral Nutrition. 42 (5): 949–459. doi:10.1002/jpen.1038. PMID 29957868.

This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by adding missing information.